BD and ChemoGLO have announced a strategic collaboration aimed at improving hazardous drug contamination testing in healthcare facilities. The partnership enables facilities to use both rapid qualitative testing and detailed quantitative analysis to identify and address potential exposure risks for healthcare workers.
The BD HD Check System provides point-of-care qualitative results in about 10 minutes. Facilities can then send collected samples to ChemoGLO, where liquid chromatography-tandem mass spectrometry (LC-MS/MS) is used to generate a comprehensive quantitative report within three to five days of sample receipt. This process is designed to offer a more complete understanding of hazardous drug contamination.
Eric Borin, worldwide president of BD Medication Delivery Solutions, stated: “With the BD HD Check System, facilities can quickly identify potential contamination, and through our collaboration with ChemoGLO, gain deeper insights into exposure risks. This dual approach helps pinpoint areas of improvement and reinforces our commitment to healthcare worker safety.”
The combined workflow from BD and ChemoGLO allows healthcare providers to monitor for contamination more effectively and respond promptly when risks are detected. The approach supports recommendations from a 2020 consensus conference on hazardous drug surface contamination, which encouraged the use of both qualitative and quantitative methods for assessing environmental safety.
Cara Zamboni, CEO at ChemoGLO, said: “At ChemoGLO, the heart of our mission has always been to protect health care workers and patients from hazardous drug exposure. By partnering with BD, we’re combining speed and precision to help facilities act faster and more confidently to safeguard their teams.”
